Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Rachael Jones, BSc, Petra Muus, MD PhD, Talha Munir, MBBS, Alexandra Pike, MBBS, Louise Arnold, Jeanifer Gachev, Briony Forrest, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140256

Published: 2020

Journal Articles

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Louise Arnold, Ray Borrow, PhD FRCPath, Kathryn Riley, Talha Munir, MBBS, Richard Kelly, BSc, MD, Rachael Jones, BSc, Jeanifer Gachev, Briony Forrest, Alexandra Pike, MBBS, Petra Muus, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141780

Published: 2020

Journal Articles

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Louise Arnold, Richard Kelly, BSc, MD, Talha Munir, MBBS, Petra Muus, MD PhD, Alexandra Pike, MBBS, Kathryn Riley, Briony Forrest, Jeanifer Gachev, Morag Griffin, MBChB, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141769

Published: 2020

Journal Articles

Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations

Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Jie Jiang, PhD, Simon Slade, BSc, Austin Kulasekararaj, MD MRCP, FRCPath, Victoria Potter, BSc, MBBS, FRCPA, Varun Mehra, MBBS,MRCP,FRCPath, Petra Muus, MD PhD, Andrea Da Silva, MBBS, Sudarshan Gurung, MBBS, MRCP, Alice Mason, B.Pharm, Aytug Kizilors, PhD, Nicholas Lea, PhD, Sahar Mansour, MD, Robin M. Ireland, MBBS, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Judith Marsh, MD FRCPath

Blood (2019) 134 (Supplement_1): 3749.

https://doi.org/10.1182/blood-2019-130754

Published: 2019

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Blood (2016) 128 (22): 224.

https://doi.org/10.1182/blood.V128.22.224.224

Published: 2016

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin

Saskia Langemeijer, MD PhD, Jun-Ichi Nishimura, MD PhD, Wynne Weston-Davies, Miles A Nunn, DPhil, Yuzuru Kanakura, MD PhD, Ian J Mackie, Petra Muus, MD PhD

Blood (2015) 126 (23): 1209.

https://doi.org/10.1182/blood.V126.23.1209.1209

Published: 2015

Journal Articles

Patients with Paroxysmal Nocturnal Hemoglobinuria and Hemolysis Demonstrate More Frequent Disease-Related Features Than Those without Hemolysis, but Similar Proportions Experience Thromboembolism

Mustafa Nuri Yenerel, MD, Petra Muus, MD PhD, Amanda Wilson, MPH, PhD, Jeff Szer, MB, BS, FRACP

Blood (2015) 126 (23): 3339.

https://doi.org/10.1182/blood.V126.23.3339.3339

Published: 2015

Journal Articles

Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Antonio Medina Almeida, MD PhD, Camille L. Bedrosian, MD, Alexander Cole, DSc, MPH, Petra Muus, MD PhD, Hubert Schrezenmeier, MD, Jeff Szer, MB, BS, FRACP, Alvaro Urbano-Ispizua, MD PhD, Wendell F. Rosse, MD

Blood (2015) 126 (23): 3340.

https://doi.org/10.1182/blood.V126.23.3340.3340

Published: 2015

Journal Articles

Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients

Alvaro Urbano-Ispizua, Petra Muus, MD PhD, Hubert Schrezenmeier, MD, Antonio Medina Almeida, MD PhD, Amanda Wilson, MPH, PhD, Russell E. Ware, MD PhD

Blood (2015) 126 (23): 3341.

https://doi.org/10.1182/blood.V126.23.3341.3341

Published: 2015

Journal Articles

Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Richard J Kelly, MBChB, PhD, Britta Höchsmann, MD, Austin Kulasekararaj, Sophie de Guibert, MD, Alexander Röth, MD, Ilene C Weitz, MD, Elina Armstrong, MD PhD, Anita Hill, MBChB, PhD, Antonio M. Risitano, MD PhD, Christopher J Patriquin, MDFRCPC, Louis Terriou, MD, Petra Muus, MD PhD, Michelle P Turner, MS in Biostatistics, Hubert Schrezenmeier, MD PhD, Jeffrey Szer, MB BS FRACP, Regis Peffault de Latour, MD PhD

Blood (2014) 124 (21): 4393.

https://doi.org/10.1182/blood.V124.21.4393.4393

Published: 2014

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group

Eline MP Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian JPL Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MDPhD, Saskia K. Klein, MDPhD, Pierre W. Wijermans, MDPhD, Georgine E De Greef, Marie-Cecile Legdeur, MD PhD, Petra Muus, MD PhD, Gert J Ossenkoppele, MD PhD, Joop H Jansen, PhD, Arjan A Van de Loosdrecht, MD PhD

Blood (2014) 124 (21): 4667.

https://doi.org/10.1182/blood.V124.21.4667.4667

Published: 2014

Journal Articles

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Eline M.P. Cremers, MD, Theresia M. Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A. Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MD, PhD, Saskia K. Klein, MD PhD, Pierre W. Wijermans, MD, PhD, Georgine E. de Greef, MD, PhD, Martijn R. Schaafsma, MD, PhD, M Marwijk Kooy, MD, PhD, Petra Muus, MD, PhD, Gert J. Ossenkoppele, MD PhD, Joop H. Jansen, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2013) 122 (21): 1521.

https://doi.org/10.1182/blood.V122.21.1521.1521

Published: 2013

Journal Articles

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Heiko Becker, MD, Stefan Suciu, PhD, Björn Rüter, MD, Uwe Platzbecker, MD, PhD, Aristoteles Giagounidis, MD, Dominik Selleslag, MD, Boris Labar, MD, PhD, Ulrich Germing, MD, Helmut R. Salih, MD, Petra Muus, MD, PhD, Karl-Heinz Pflüger, MD, Anne Hagemeijer, MD, PhD, Hans-Eckart Schaefer, MD, Frédéric Baron, MD, PhD, Arnold Ganser, MD, Carlo Aul, MD, Theo de Witte, MD, Pierre W. Wijermans, MD, Michael Lübbert, MD

Blood (2013) 122 (21): 1452.

https://doi.org/10.1182/blood.V122.21.1452.1452

Published: 2013

Journal Articles

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, Yahsou Delmas, MD, Maria Herthelius, MD, Camille L. Bedrosian, MD, Chantel Loirat

Blood (2013) 122 (21): 2186.

https://doi.org/10.1182/blood.V122.21.2186.2186

Published: 2013

Journal Articles

Neutrophil Extracellular Trap Formation In PNH Patients With and Without a History Of Thrombosis - Effects Of Eculizumab

Sacha Zeerleder, MD, PhD, Sandra van Bijnen, MD, Diana Wouters, PhD, Gerard J van Mierlo, Petra Muus, MD, PhD

Blood (2013) 122 (21): 1235.

https://doi.org/10.1182/blood.V122.21.1235.1235

Published: 2013

Journal Articles

Time To Hematologic and Renal Improvements In aHUS Patients With Progressing Thrombotic Microangiopathy Treated With Eculizumab Over Two Years

Petra Muus, MD, PhD, Camille L. Bedrosian, MD, Richard R. Furman, MD, Christophe Legendre, Chantel Loirat

Blood (2013) 122 (21): 3426.

https://doi.org/10.1182/blood.V122.21.3426.3426

Published: 2013

NARROW

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin

Patients with Paroxysmal Nocturnal Hemoglobinuria and Hemolysis Demonstrate More Frequent Disease-Related Features Than Those without Hemolysis, but Similar Proportions Experience Thromboembolism

Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients

Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Neutrophil Extracellular Trap Formation In PNH Patients With and Without a History Of Thrombosis - Effects Of Eculizumab

Time To Hematologic and Renal Improvements In aHUS Patients With Progressing Thrombotic Microangiopathy Treated With Eculizumab Over Two Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only